Retinoic Acid Receptors

[1]  P. Brown,et al.  The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice , 2008, British Journal of Cancer.

[2]  P. Pandolfi,et al.  RARα-PLZF overcomes PLZF-mediated repression of CRABPI, contributing to retinoid resistance in t(11;17) acute promyelocytic leukemia , 2007, Proceedings of the National Academy of Sciences.

[3]  L. Altucci,et al.  RAR and RXR modulation in cancer and metabolic disease , 2007, Nature Reviews Drug Discovery.

[4]  Jorge Cortes,et al.  Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. , 2007, Blood.

[5]  Lucia Altucci,et al.  Design of selective nuclear receptor modulators: RAR and RXR as a case study , 2007, Nature Reviews Drug Discovery.

[6]  R. Nasr,et al.  RXR is an essential component of the oncogenic PML/RARA complex in vivo. , 2007, Cancer cell.

[7]  C. Chomienne,et al.  Epigenetic patterns of the retinoic acid receptor β2 promoter in retinoic acid-resistant thyroid cancer cells , 2007, Oncogene.

[8]  S. Lalevée,et al.  Protein kinases and the proteasome join in the combinatorial control of transcription by nuclear retinoic acid receptors. , 2007, Trends in cell biology.

[9]  I. Bozzoni,et al.  Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia. , 2007, Blood.

[10]  L. Manchon,et al.  Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivity. , 2007, Blood.

[11]  Vamsi K. Gangaraju,et al.  Mechanisms of ATP dependent chromatin remodeling. , 2007, Mutation research.

[12]  E. Dmitrovsky,et al.  A Proof-of-Principle Clinical Trial of Bexarotene in Patients with Non–Small Cell Lung Cancer , 2007, Clinical Cancer Research.

[13]  S. Hilsenbeck,et al.  Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays. , 2006, Cancer research.

[14]  J. Crowley,et al.  Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  F. Ferrari,et al.  Identification of a molecular signature predictive of sensitivity to differentiation induction in acute myeloid leukemia , 2006, Leukemia.

[16]  F. Mandelli,et al.  Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. , 2006, Cancer research.

[17]  E Marubini,et al.  Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  P. Purushottamachar,et al.  Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases. , 2006, Bioorganic & medicinal chemistry.

[19]  P. Chambon,et al.  Function of retinoid nuclear receptors: lessons from genetic and pharmacological dissections of the retinoic acid signaling pathway during mouse embryogenesis. , 2006, Annual review of pharmacology and toxicology.

[20]  Zhihua Liu,et al.  5-Aza-2'-deoxycytidine induces retinoic acid receptor-beta(2) demethylation and growth inhibition in esophageal squamous carcinoma cells. , 2005, Cancer letters.

[21]  C. Schoch,et al.  Clinical trial of valproic acid and all‐trans retinoic acid in patients with poor‐risk acute myeloid leukemia , 2005, Cancer.

[22]  L. Altucci,et al.  Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor. , 2005, Cancer research.

[23]  J. Bastien,et al.  Phosphorylation of the retinoid x receptor at the omega loop, modulates the expression of retinoic-acid-target genes with a promoter context specificity. , 2005, Cellular signalling.

[24]  M. Edelman,et al.  Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  F. Khuri,et al.  Activation of Nuclear Factor-κB Contributes to Induction of Death Receptors and Apoptosis by the Synthetic Retinoid CD437 in DU145 Human Prostate Cancer Cells , 2005 .

[26]  D. Bowtell,et al.  The retinoid anticancer signal: mechanisms of target gene regulation , 2005, British Journal of Cancer.

[27]  Pierre Chambon,et al.  The nuclear receptor superfamily: a personal retrospect on the first two decades. , 2005, Molecular endocrinology.

[28]  Charles Auffray,et al.  Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Natalia Meani,et al.  Molecular signature of retinoic acid treatment in acute promyelocytic leukemia , 2005, Oncogene.

[30]  Satish K. Tickoo,et al.  Retinoic Acid and the Histone Deacetylase Inhibitor Trichostatin A Inhibit the Proliferation of Human Renal Cell Carcinoma in a Xenograft Tumor Model , 2005, Clinical Cancer Research.

[31]  S. Lalevée,et al.  Vinexin β Interacts with the Non-phosphorylated AF-1 Domain of Retinoid Receptor γ (RARγ) and Represses RARγ-mediated Transcription* , 2005, Journal of Biological Chemistry.

[32]  S. Kogan,et al.  A sumoylation site in PML/RARA is essential for leukemic transformation. , 2005, Cancer cell.

[33]  A. Szántó,et al.  Retinoid X receptors: X-ploring their (patho)physiological functions , 2004, Cell Death and Differentiation.

[34]  H. Gronemeyer,et al.  Tumor suppressor IRF‐1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL , 2004, The EMBO journal.

[35]  Y. Byun,et al.  The effect of cellular retinoic acid binding protein-I expression on the CYP26-mediated catabolism of all-trans retinoic acid and cell proliferation in head and neck squamous cell carcinoma. , 2004, Metabolism: clinical and experimental.

[36]  R. Eckert,et al.  Suppression of human pancreatic cancer cell proliferation by AGN194204, an RXR-selective retinoid. , 2004, Carcinogenesis.

[37]  D. Crowe,et al.  A retinoid X receptor (RXR)-selective retinoid reveals that RXR-α is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands , 2004, Breast Cancer Research.

[38]  L. Kopelovich,et al.  Topical Tazarotene Chemoprevention Reduces Basal Cell Carcinoma Number and Size in Ptch1+/− Mice Exposed to Ultraviolet or Ionizing Radiation , 2004, Cancer Research.

[39]  S. Friedman,et al.  Acyclic retinoid in the chemoprevention of hepatocellular carcinoma (review). , 2004, International journal of oncology.

[40]  Rama Ranganathan,et al.  Structural Determinants of Allosteric Ligand Activation in RXR Heterodimers , 2004, Cell.

[41]  D. Reinberg,et al.  The mediator coactivator complex: functional and physical roles in transcriptional regulation , 2003, Journal of Cell Science.

[42]  C. Rochette-Egly.  Nuclear receptors: integration of multiple signalling pathways through phosphorylation. , 2003, Cellular signalling.

[43]  E. Winer,et al.  Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  C. Chomienne,et al.  Cyclin D3 Is a Cofactor of Retinoic Acid Receptors, Modulating Their Activity in the Presence of Cellular Retinoic Acid-binding Protein II* , 2003, The Journal of Biological Chemistry.

[45]  R. Blomhoff,et al.  Gene expression regulation by retinoic acid Published, JLR Papers in Press, August 16, 2002. DOI 10.1194/jlr.R100015-JLR200 , 2002, Journal of Lipid Research.

[46]  M. Gerstein,et al.  Genomic and proteomic analysis of the myeloid differentiation program: global analysis of gene expression during induced differentiation in the MPRO cell line. , 2002, Blood.

[47]  Arvind Virmani,et al.  Loss of retinoic acid receptor beta gene expression is linked to aberrant histone H3 acetylation in lung cancer cell lines. , 2002, Cancer research.

[48]  P. Chambon,et al.  Phosphorylation by p38MAPK and recruitment of SUG‐1 are required for RA‐induced RARγ degradation and transactivation , 2002, The EMBO journal.

[49]  R. H. Gross,et al.  Developmentally-related candidate retinoic acid target genes regulated early during neuronal differentiation of human embryonal carcinoma , 2002, Oncogene.

[50]  M. Dawson,et al.  Discovery and design of retinoic acid receptor and retinoid X receptor class- and subtype-selective synthetic analogs of all-trans-retinoic acid and 9-cis-retinoic acid. , 2002, Current medicinal chemistry.

[51]  S. Minucci,et al.  Methyltransferase Recruitment and DNA Hypermethylation of Target Promoters by an Oncogenic Transcription Factor , 2002, Science.

[52]  S. Chevret,et al.  In vitro all-trans retinoic acid sensitivity of acute promyelocytic leukemia blasts: a novel indicator of poor patient outcome. , 2001, Blood.

[53]  C. Chomienne,et al.  The novel co‐activator CRABPII binds to RARα and RXRα via two nuclear receptor interacting domains and does not require the AF‐2 ‘core’ , 2001 .

[54]  J. Licht,et al.  Translocations of the RARα gene in acute promyelocytic leukemia , 2001, Oncogene.

[55]  L. Altucci,et al.  Autonomous rexinoid death signaling is suppressed by converging signaling pathways in immature leukemia cells. , 2001, Molecular endocrinology.

[56]  G. Snow,et al.  Expression of retinoic acid receptor gamma correlates with retinoic acid sensitivity and metabolism in head and neck squamous cell carcinoma cell lines , 2001, International journal of cancer.

[57]  L. Altucci,et al.  Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL , 2001, Nature Medicine.

[58]  P. Pandolfi,et al.  Role of PML and PML-RARα in Mad-Mediated Transcriptional Repression , 2001 .

[59]  F. Dilworth,et al.  Nuclear receptors coordinate the activities of chromatin remodeling complexes and coactivators to facilitate initiation of transcription , 2001, Oncogene.

[60]  R. Figlin,et al.  Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  M. Duvic,et al.  Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  M. Dawson,et al.  Induction of Egr-1 expression by the retinoid AHPN in human lung carcinoma cells is dependent on activated ERK1/2 , 2001, Cell Death and Differentiation.

[63]  John Calvin Reed,et al.  Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. , 2000, Science.

[64]  P. Chambon,et al.  TFIIH Interacts with the Retinoic Acid Receptor γ and Phosphorylates Its AF-1-activating Domain through cdk7* , 2000, The Journal of Biological Chemistry.

[65]  S. Minucci,et al.  Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. , 2000, Molecular cell.

[66]  R. Evans,et al.  Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. , 2000, Molecular cell.

[67]  S. Sukumar,et al.  Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor β2 promoter in breast cancer cells , 2000, Oncogene.

[68]  S. Khorasanizadeh,et al.  Structure of the RXR–RAR DNA‐binding complex on the retinoic acid response element DR1 , 2000, The EMBO journal.

[69]  D. Xiao,et al.  Orphan Receptor COUP-TF Is Required for Induction of Retinoic Acid Receptor β, Growth Inhibition, and Apoptosis by Retinoic Acid in Cancer Cells , 2000, Molecular and Cellular Biology.

[70]  C. Allis,et al.  The language of covalent histone modifications , 2000, Nature.

[71]  M. Koken,et al.  Retinoic Acid Induces Proteasome-Dependent Degradation of Retinoic Acid Receptor α (RARα) and Oncogenic RARα Fusion Proteins , 1999 .

[72]  P. Chambon,et al.  Physical and Functional Interactions between Cellular Retinoic Acid Binding Protein II and the Retinoic Acid-Dependent Nuclear Complex , 1999, Molecular and Cellular Biology.

[73]  P. Chambon,et al.  Hyperphosphorylation of the Retinoid X Receptor α by Activated c-Jun NH2-terminal Kinases* , 1999, The Journal of Biological Chemistry.

[74]  K. Umesono,et al.  A Unified Nomenclature System for the Nuclear Receptor Superfamily , 1999, Cell.

[75]  P. Chambon,et al.  Embryonic retinoic acid synthesis is essential for early mouse post-implantation development , 1999, Nature Genetics.

[76]  Shujian Wu,et al.  Critical role of both retinoid nuclear receptors and retinoid-X-receptors in mediating growth inhibition of ovarian cancer cells by all-trans retinoic acid , 1998, Oncogene.

[77]  P. Pandolfi,et al.  Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. , 1998, Journal of the National Cancer Institute.

[78]  D. Sinnett,et al.  Demethylation by 5-aza-2´-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor ß gene in human colon carcinoma cells , 1998, Anti-cancer drugs.

[79]  P. Pelicci,et al.  Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein. , 1998, Blood.

[80]  S. Minucci,et al.  Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia , 1998, Nature.

[81]  C. Tribioli,et al.  Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL , 1998, Nature Genetics.

[82]  M. Dawson,et al.  Regulation of RARβ expression by RAR‐ and RXR‐selective retinoids in human lung cancer cell lines: Effect on growth inhibition and apoptosis induction , 1998, International journal of cancer.

[83]  G. Hortobagyi,et al.  Progressive decrease in nuclear retinoic acid receptor beta messenger RNA level during breast carcinogenesis. , 1997, Cancer research.

[84]  L. Castillo,et al.  Analysis of retinoic acid receptor beta expression in normal and malignant laryngeal mucosa by a sensitive and routine applicable reverse transcription-polymerase chain reaction enzyme-linked immunosorbent assay method. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[85]  M. Widschwendter,et al.  Loss of retinoic acid receptor beta expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer. , 1997, Cancer research.

[86]  R. Lotan,et al.  Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: implications for lung cancer development. , 1997, Journal of the National Cancer Institute.

[87]  C. Niu,et al.  Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. , 1997, Blood.

[88]  Mi-Ock Lee,et al.  Modulation of retinoic acid sensitivity in lung cancer cells through dynamic balance of orphan receptors nur77 and COUP‐TF and their heterodimerization , 1997, The EMBO journal.

[89]  R. Momparler,et al.  Activation of the retinoic acid receptor β gene by 5-aza-2’-deoxycytidine in human DLD-1 colon carcinoma cells , 1997, Anti-cancer drugs.

[90]  T. Naoe,et al.  In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins , 1996 .

[91]  R. Kothary,et al.  Lung tumors in mice expressing an antisense RARβ2 transgene , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[92]  J. L. Napoli.  Retinoic acid biosynthesis and metabolism , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[93]  R. Pine,et al.  Retinoic acid activates interferon regulatory factor-1 gene expression in myeloid cells. , 1996, Blood.

[94]  John Calvin Reed,et al.  Retinoic acid receptor beta mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells , 1996, Molecular and cellular biology.

[95]  P. Chambon,et al.  Differential ligand‐dependent interactions between the AF‐2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1. , 1996, The EMBO journal.

[96]  Myles Brown,et al.  Polarity-specific activities of retinoic acid receptors determined by a co-repressor , 1995, Nature.

[97]  P. Fenaux,et al.  All-trans retinoic acid pharmacokinetics and bioavailability in acute promyelocytic leukemia: intracellular concentrations and biologic response relationship. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  M. Gaub,et al.  Characterization of nuclear retinoic acid binding activity in sensitive leukemic cell lines: cell specific uptake of ATRA and RAR alpha protein modulation. , 1995, Biochemical and Biophysical Research Communications - BBRC.

[99]  P. Chambon,et al.  Phosphorylation of the retinoic acid receptor-alpha by protein kinase A. , 1995, Molecular endocrinology.

[100]  J S Lee,et al.  Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. , 1995, The New England journal of medicine.

[101]  P. Chambon,et al.  RAR‐specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage‐independent cell proliferation. , 1995, The EMBO journal.

[102]  L. Gudas,et al.  Vitamin A, differentiation and cancer. , 1994, Current opinion in cell biology.

[103]  L. Gaboury,et al.  Hyperplasia and tumours in lung, breast and other tissues in mice carrying a RAR beta 4‐like transgene. , 1994, The EMBO journal.

[104]  P. Fenaux,et al.  Modulation of IL-8, IL-1 beta, and G-CSF secretion by all-trans retinoic acid in acute promyelocytic leukemia. , 1994, Leukemia.

[105]  P. Fenaux,et al.  Hematopoietic growth factor expression and ATRA sensitivity in acute promyelocytic blast cells , 1994 .

[106]  A. Dejean,et al.  The PML-RARα gene product of the t(15;17) translocation inhibits retinoic acid-induced granulocytic differentiation and mediated transactivation in human myeloid cells , 1994 .

[107]  Z. Dong,et al.  Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[108]  J. Lehmann,et al.  Retinoids selective for retinoid X receptor response pathways. , 1992, Science.

[109]  P. Chambon,et al.  Multiplicity generates diversity in the retinoic acid signalling pathways. , 1992, Trends in biochemical sciences.

[110]  R. Evans,et al.  Characterization of three RXR genes that mediate the action of 9-cis retinoic acid. , 1992, Genes & development.

[111]  Gregor Eichele,et al.  9-cis retinoic acid is a high affinity ligand for the retinoid X receptor , 1992, Cell.

[112]  H. de Thé,et al.  All-trans retinoic acid modulates the retinoic acid receptor-alpha in promyelocytic cells. , 1991, The Journal of clinical investigation.

[113]  H. Dombret,et al.  Treatment of first relapse in acute promyelocytic leukaemia with all-trans retinoic acid , 1990, The Lancet.

[114]  P. Chambon,et al.  Retinoic acid receptors and cellular retinoid binding proteins. I. A systematic study of their differential pattern of transcription during mouse organogenesis. , 1990, Development.

[115]  R Berger,et al.  All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. , 1990, Blood.

[116]  H. Stunnenberg,et al.  Identification of a retinoic acid responsive element in the retinoic acid receptor & beta;gene , 1990, Nature.

[117]  R. Berger,et al.  RETINOIC ACID THERAPY FOR PROMYELOCYTIC LEUKAEMIA , 1989, The Lancet.

[118]  C. Steidl,et al.  The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all‐trans retinoic acid in patients with acute myeloid leukemia , 2006, Cancer.

[119]  P. Fenaux,et al.  All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship. , 1990, Blood.

[120]  R. Lotan,et al.  Retinoids and their receptors in cancer development and chemoprevention. , 2002, Critical reviews in oncology/hematology.

[121]  P G Pelicci,et al.  Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. , 2001, Cancer research.

[122]  H. Dombret,et al.  Functional G-CSF pathways in t(8;21) leukemic cells allow for differentiation induction and degradation of AML1-ETO. , 2000, The hematology journal : the official journal of the European Haematology Association.

[123]  A. Agadir,et al.  Differential uptake of all-trans retinoic acid by acute promyelocytic leukemic cells: evidence for its role in retinoic acid efficacy. , 1995, Leukemia.

[124]  P. Predki,et al.  Ordered binding of retinoic acid and retinoid-X receptors to asymmetric response elements involves determinants adjacent to the DNA-binding domain. , 1994, Molecular endocrinology.